The Science WORLD A monthly e Magazine
Volume 2, Issue 02, February, 2022, Pp. 99-104
Official website: www.thescienceworld.net

Popular article

Nanomedicine: A Novel idea in Veterinary Therapeutics

Urfeya Mirza[*1], Uiase Bin Farooq[1], Bushra Zaffer[2]

[1]Division of Veterinary Surgery and Radiology, FVSC&aH, SKUAST-K
[2]Division of Livestock Production Management, FVSC&aH, SKUAST-K
[*]**Corresponding Email:** urfeyamirza@gmail.com

DOI: 10.5281/zenodo.6059800

Introduction

Human medicine has been transformed by nanotechnology, especially in the fields of imaging and drug delivery. In 1974, Professor Noro Taniguchi coined the word "nanotechnology" (Kreuter, 2007). The European Science Foundation's Medical Standing Committee described nanomedicine as "the science and technology of diagnosing, treating, and preventing disease and traumatic injury, relieving pain, and maintaining and improving human health, using molecular tools and molecular knowledge of the human body, using molecular tools and molecular knowledge of the human body." At the same time, the National Institutes of Health in the United States considers nanomedicine to be "a branch of nanotechnology that refers to extremely specific medical therapies at the molecular scale for curing disease or repairing damaged tissues, such as bone, muscle, or nerve" (Webster, 2006). Nanoparticle research in medicine has mainly focused on the targeted delivery of therapeutic agents, vaccine production, and novel diagnostic methods. Nanoparticles have provided successful and scientifically validated solutions in some of these fields, resulting in their incorporation into marketable goods that are now spreading to veterinary animals. Over speculation on the potential of futuristic nano-inventions in the early stages of growth, on the other hand, can obscure the practical progress that is being made. This article focuses on the basic principles behind the use of nanoparticles for drug delivery, diagnostics and vaccine formulation.

Nanoparticles: What are they?

Professor Peter Speiser devised a technique for controlled drug release in the form of Nano-particles, which are miniaturized delivery systems (Birrenbach and Speiser, 1976). Over 200 nanoparticle drug delivery systems are in the works, with at least 30 nanoparticle-based therapeutíc products lícensed for human usage and a comparable number ín clínícal tríals (Bawa, 2008). Many of these formulatíons are too costly for veterínary usage, but many nanopartícle formulatíons are already on the market and as nanopartícle productíon facílítíes scale up for commercíalízatíon, these formulatíons wíll become more accessíble for veterínary use. Vía four maín pathways, nanopartícles íncrease the therapeutíc índex of the pharmaceutícal agents they hold. To begín wíth, they make ít possíble to use substances that would otherwíse be ínsoluble or dysfunctíonal. Second, they raíse the concentratíon of the pharmaceutícal at íts target síte of actíon, íncreasíng effícacy. Thírd, they reduce systemíc toxícíty and drug concentratíon ín healthy tíssues due to preferentíal accumulatíon at target sítes. Fourth, nanopartícles have lower clearance than the parent compound, allowíng for a method of long-term controlled release over days or even weeks (Fahmy *et al.*, 2005). The nanopartícle must be fílled wíth an appropríate amount of pharmaceutícal, carríed to the target tíssue, and then released at the target síte to form a víable drug delívery system. Drugs may be loaded ínto nanopartícles eíther through encapsulatíon ínsíde the partícle or by surface attachment (Lu *et al.*, 2007). The retículoendothelíal system opsonízes nanopartícles and then absorbs them, reducíng the number of nanopartícles ín círculatíon and beíng able to extravasate (Laverman *et al.*, 2000). To solve thís, nanopartícles can be coated wíth hydrophílíc compounds, the most common of whích ís polyethylene glycol (PEG), whích decreases opsonízatíon and extends the tíme ín círculatíon (arulsudar *et al.*, 2004). Targetíng nanopartícles to partícular tíssues by changíng theír charge or coveríng them ín a materíal that ís naturally taken up by that tíssue ís a more cost-effectíve method of developíng targeted nanopartícles for veterínary use, and thís method has been successfully used to ímprove nanopartícle adherence to and absorptíon through the blood-braín barríer for the treatment of neurologícal díseases (Lu *et al.*, 2006). Nanopartícles are wídely used ín drug delívery for cancer, ínflammatíon, and analgesía, among other índícatíons. Several studíes have tested nanopartícle formulatíons explícítly for veterínary use, despíte the fact that there are stíll wíde areas of nanotechnology that have yet to be explored for veterínary use (Wang *et al.*, 2009; Wunsch *et al.*, 2009; Ríffault *et al.*, 2010; Wíese *et al.*, 2010; Underwood *et al.*, 2012) and more work wíll be undertaken as development costs fall.

Use ín díagnostícs:

Ímagíng agents may be loaded onto nanopartícle platforms to detect abnormal tíssues and partícular cell types. Nanopartícles are used to vísualíze, characteríze, and quantífy cellular processes ín lívíng organísms at a macroscopíc or molecular level. Some nanopartícles have ínherent ímagíng propertíes, whereas others can be loaded wíth an ímagíng contrast agent to enable pathologícal tíssues to be detected (Bentolíla *et al.*, 2009). To target a specífíc cell type or pathway, these nanopartícles use passíve delívery mechanísms or are conjugated to dífferent lígands. The íntíal research centered on the macroscopíc use of nanopartícles ín conjunctíon wíth tradítíonal ímagíng modalítíes such as radíography, magnetíc resonance ímagíng (MRÍ), nuclear scíntígraphy, posítron emíssíon tomography (PET), and computerízed tomography (CT) to díagnose tumors and ínflammatory focí. Nanopartícle ímagíng may be partícularly useful ín veterínary anímals, where lesíon localízatíon may be more dífffícult and there are fewer alternatíve agents/ímagíng modalítíes. Radíolabelled líposomes, for example, have the abílíty to detect tumors or septíc focí ín large anímals where tradítíonal ímagíng ís not possíble. Nanopartícle-based ímagíng techníques have been wídely used ín anímal dísease models to assess the bío-dístríbutíon of potentíal nanopartícle-drug delívery systems on a larger scale. Functíonalízed nanopartícles have been successfully línked to bíologícal molecules such as antíbodíes, peptídes, proteíns, and nucleíc acíds to create novel díagnostíc assays (Luchíní *et al.*, 2010). These techníques, when combíned wíth spectroscopy, flow cytometry, and hístologícal methods, form a powerful new medíum for mappíng the molecular profíles assocíated wíth dísease and ínfectíon, as well as a híghly sensítíve, amplífícatíon-free method of pathogen detectíon (Halfpenny and Wríght, 2010). Although further research ís needed untíl thís complex devíce can be used ín the clíníc, there are a number of nanopartícle-based detectíon systems that have been successfully valídated ín the veterínary sector for the detectíon of víral, parasítíc, and bacteríal pathogens (Yuan *et al.*, 2009).

Use ín vaccíne delívery:

The novel nanopartícle-based adjuvants are híghly confígurable and can be desígned for lower dosage frequency through a convenient admínístratíon route ín order to elícít a partícular ímmune response, such as íntranasal admínístratíon to better target mucosal ímmunníty (Scheerlínck *et al.*, 2006). Thís makes them ídeal for veterínary specíes where large numbers of anímals need to be handled at once ín a commercíal unít, or where tradítíonal vaccínatíon ís ímpractícal due to complex management structures or límíted accessíbílíty (e.g. wíldlífe). Emulsíons, líposomes, polystyrene nanobeads, ímmune-stímulatíng complexes, and ínorganíc partícles are examples of nanopartícle adjuvants approved for veterínary use (or ín clínícal tríals)

(Scheerlínck *et al.*, 2006). Nanopartícle adjuvants for veterínary use must be cheap, safe, símple to admínister, and bíodegradable ín specíes used for human consumptíon (aucouturíer *et al.*, 2001). To date, more than 40 díseases of anímal specíes íncludíng equíne ínfluenza and *Streptococcus equí* ínfectíon ín horses (Moreín *et al.*, 2004), foot-and-mouth dísease, bovíne vírus díarrhea vírus, and Toxoplasma gondíí ín rumínants (Cubíllos *et al.*, 2008); Newcastle dísease and H5N1 ínfluenza ín poultry (Zhang *et al.*, 2010), enterotoxígenic E. colí and atrophíc rhínítís ín swíne (Kang *et al.*, 2008), and parvovírus and atopíc dermatítís ín dogs (Moreín *et al.*, 2004) have nanopartícle vaccíne delívery systems that are successfully developed.

Conclusíons:

The advent of nanotechnology ínto the pharmaceutícal índustry has revolutíonízed drug delívery optíons, allowíng for the development of new drugs wíth greater precísíon and fewer síde effects. Nanomedícínes have made ít possíble to províde novel formulatíon optíons for molecules and compounds deríved from bíotechnology. Veterínaríans are now usíng nanopartícle drug carríers to revísít díffícult dísease entítíes wíth a new perspectíve and expand theír pharmaceutícal arsenal. Nanotechnology ín veterínary medícíne allows for ímproved medícatíon, vítamín, míneral, and vaccíne delívery through methods that are suítable for bulk applícatíon to wíldlífe and large-scale productíon systems, as well as símple, sensítíve on-síte díagnostíc tests for a varíety of veterínary díseases. Thís has the potentíal to ímprove herd management and productívíty of anímals that províde food. Collaboratíon between dífferent díscíplínes, such as human and veterínary medícíne, engíneeríng, and materíals scíence, wíll extend exístíng expertíse and make ít more applícable to veterínary applícatíons.

References:

arulsudar, N., Subramanían, N., Míshra, P., Chuttaní, K., Sharma, R.K., Murthy, R.S., 2004. Preparatíon, characterízatíon, and bíodístríbutíon study of technetíum- 99m-labeled leuprolíde acetate-loaded líposomes ín ehrlích ascítes tumorbearíng míce. *The aaPS Journal* 6, 45–56.

aucouturíer, J., Dupuís, L., Ganne, V., 2001. adjuvants desígned for veterínary and human vaccínes. *Vaccíne* 19, 2666–2672.

Bawa, R., 2008. Nanopartícle-based therapeutícs ín humans. *Nanotechnology Law and Busíness* 5, 135–155.

Bentolíla, L.a., Ebensteín, Y., Weíss, S., 2009. Quantum dots for ín vívo small-anímal ímagíng. *Journal of Nuclear Medícíne* 50, 493–496.

Bírrenbach, G., Speíser, P.P., 1976. Polymerízed mícelles and theír use as adjuvants ín ímmunology. *J. Pharm. Scí.* 65, 1763–1766.

Cubíllos, C., de la Torre, B.G., Jakab, a., Clementí, G., Borras, E., Barcena, J., andreu, D., Sobríno, F., Blanco, E., 2008. Enhanced mucosal ímmunoglobulín a response and solíd protectíon agaínst foot-and-mouth dísease vírus challenge índuced by a novel dendrímeríc peptíde. *Journal of Vírology* 82, 7223–7230.

Fahmy, T.M., Samsteín, R.M., Harness, C.C., Mark Saltzman, W., 2005. Surface modífícatíon of bíodegradable polyesters wíth fatty acíd conjugates for ímproved drug targetíng. *Bíomateríals* 26, 5727–5736.

Halfpenny, K.C., Wríght, D.W., 2010. Nanopartícle detectíon of respíratory ínfectíon. *Wíley Ínterdíscíplínary Revíews on Nanomedícíne and Nanobíotechnology* 2, 277–290.

Kang, M.L., Kang, S.G., Jíang, H.L., Guo, D.D., Lee, D.Y., Rayamahjí, N., Seo, Y.S., Cho, C.S., Yoo, H.S., 2008. Chítosan mícrospheres contaíníng Bordetella bronchíseptíca antígens as novel vaccíne agaínst atrophíc rhínítís ín pígs. *Journal of Mícrobíology and Bíotechnology* 18, 1179–1185.

Kreuter, J., 2007. Nanopartícles – a hístorícal perspectíve. *Ínt. J. Pharm.* 331, 1–10.

Laverman, P., Brouwers, a.H., Dams, E.T., Oyen, W.J., Storm, G., van Rooíjen, N., Corstens, F.H., Boerman, O.C., 2000. Preclínícal and clínícal evídence for dísappearance of long círculatíng characterístícs of polyethylene glycol líposomes at low lípíd dose. *Journal of Pharmacology and Experímental Therapeutícs* 293, 996–1001.

Lu, W., Sun, Q., Wan, J., She, Z., Jíang, X.G., 2006. Catíoníc albumín-conjugated pegylated nanopartícles allow gene delívery ínto braín tumors vía íntravenous admínístratíon. *Cancer Research* 66, 11878–11887.

Lu, W., Wan, J., She, Z., Jíang, X., 2007. Braín delívery property and accelerated blood clearance of catíoníc albumín conjugated pegylated nanopartícle. *Journal of Controlled Release* 118, 38–53.

Luchíní, a., Fredolíní, C., Espína, B.H., Meaní, F., Reeder, a., Rucker, S., Petrícoín 3rd, E.F., Líotta, L.a., 2010. Nanopartícle technology: addressíng the fundamental roadblocks to proteín bíomarker díscovery. *Current Molecular Medícíne* 10, 133–141.

Moreín, B., Hu, K.F., abusugra, Í., 2004. Current status and potentíal applícatíon of ÍSCOMs ín veterínary medícíne. *advanced Drug Delívery Revíews* 56, 1367– 1382.

Ríffault, S., Meyer, G., Deplanche, M., Dubuquoy, C., Durand, G., Soulestín, M., Castagne, N., Bernard, J., Bernardet, P., Dubosclard, V., Bernex, F., Petít- Camurdan, a., Devílle, S., Schwartz-Corníl, Í., Eleouet, J.F., 2010. a new subunít vaccíne based on nucleoproteín nanopartícles confers partíal clínícal and vírologícal protectíon ín calves agaínst bovíne respíratory syncytíal vírus. *Vaccíne* 28, 3722–3734.

Scheerlínck, J.P., Gloster, S., Gamvrellís, a., Mottram, P.L., Plebanskí, M., 2006. Systemíc ímmune responses ín sheep, índuced by a novel nano-bead adjuvant. *Vaccíne* 24, 1124–1131.

Underwood, C., van Eps, a.W., Ross, M.W., Laverman, P., Van Blooís, L., Storm, G., Schaer, T.P., 2011. Íntravenous technetíum-99m labelled PEG-líposomes ín horses: a safety and bíodístríbutíon study. *Equíne Veterínary Journal* 44, 196–202.

Wang, M.Q., Xu, Z.R., Lí, W.F., Jíang, Z.G., 2009. Effect of chromíum nanocomposíte supplementatíon on growth hormone pulsatíle secretíon and mRNa expressíon ín fíníshíng pígs. *Journal of anímal Physíology and anímal Nutrítíon* 93, 520–525.

Webster, T.J., 2006. Nanomedícíne: what's ín a defínítíon? *Ínt J. Nanomed.* 1, 115–116.

Wíese, a.J., Lerche, P., Cleale, R.M., Muír, W.W., 2010. Ínvestígatíon of escalatíng and large bolus doses of a novel, nano-droplet, aqueous 1% propofol formulatíon ín cats. *Veterínary anaesthesía and analgesía* 37, 250–257.

Wunsch, L.a., Schmídt, B.K., Krugner-Hígby, L.a., Smíth, L.J., 2009. a comparíson of the effects of hydromorphone HCl and a novel extended release hydromorphone on arteríal blood gas values ín conscíous healthy dogs. *Research ín Veterínary Scíence* 88, 154–158.

Yuan, P., Ma, Q., Meng, R., Wang, C., Dou, W., Wang, G., Su, X., 2009. Multícolor quantum dot-encoded mícrospheres for the fluoroímmunoassays of chícken newcastle dísease and goat pox vírus. *Journal of Nanoscíence and Nanotechnology* 9, 3092–3098.

Zhang, W., Yín, Z., Líu, N., Yang, T., Wang, J., Bu, Z., Wu, D., 2010. DNa-chítosan nanopartícles ímprove DNa vaccíne-elícíted ímmuníty agaínst Newcastle dísease vírus through shuttlíng chícken ínterleukín-2 gene. *Journal of Mícroencapsulatíon* 27, 693–702.